

CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE
Interviews for the Scientific Strategic Plan

Categories of Interviewees:

- National Scientific Leaders
- Basic / Translational / Clinical Scientists
- Patient Advocates
- Foundations / Philanthropy
- Private Sector
- Public Interest

Possible Initial Interviewees:

Name	Affiliation
Bruce Alberts, Ph.D.	President, National Academy of Sciences
Susan Desmond-Hellmann, M.D., M.P.H.	President, Product Development - Genentech, Inc.
Jeffrey C. Martin, Esq.	Counsel, Goodwin & Procter, LLP Advisory Board Member, The Parkinson Alliance
Douglas Melton, Ph.D.	Thomas Dudley Cabot Professor of the Natural Sciences, Harvard University Investigator, Howard Hughes Medical Institute
William Neaves, Ph.D.	President, Chief Executive Officer, The Stowers Institute for Medical Research
Austin Smith, Ph.D.	Director, Centre for Genome Research Chair, Institute for Stem Cell Biology in Cambridge
James A. Thomson, V.M.D., Ph.D.	Professor, Department of Anatomy, Genome Center of Wisconsin Chief Pathologist, Wisconsin Regional Primate Research Center
Roy Vagelos, M.D.	Past Chairman of the Board and Chief Executive Officer, Merck & Co., Inc.
Harold Varmus, M.D.	President and Chief Executive Officer, Memorial Sloan-Kettering Cancer Center

Note: We have collected about 120 names so far, we are seeking more.

DRAFT - FOR DISCUSSION PURPOSES ONLY

SAMPLE OF POSSIBLE QUESTIONS FOR INTERVIEWEES

- How would you define success for the Institute over the next ten years?
- What are some concrete milestones (3 year, 5 year) the Institute might use to gauge its progress?
- Is there any "low hanging fruit"? That is, are there opportunities for quick, visible, low-risk successes?
- Are there specific funding structures (particularly novel ones) that will best help us achieve our objectives?
- How far along the basic / translational / clinical research continuum should the CIRM aspire to move? What mechanisms should the Institute use to allow others to pick up where it leaves off?
- How can CIRM maximize the impact of California's investment in stem cell research through interstate and international collaborations?